Bryn Mawr Trust CO Xeris Biopharma Holdings, Inc. Transaction History
Bryn Mawr Trust CO
- $5.44 Billion
- Q4 2024
A detailed history of Bryn Mawr Trust CO transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 40 shares of XERS stock, worth $143. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40
Previous 40
-0.0%
Holding current value
$143
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding XERS
# of Institutions
152Shares Held
60MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$28.3 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$18.3 Million62.59% of portfolio
-
Geode Capital Management, LLC Boston, MA3.35MShares$12 Million0.0% of portfolio
-
State Street Corp Boston, MA3.2MShares$11.5 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $487M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...